外来がん化学療法登録レジメン頭頸部癌 Cetuximab+CBDCA+5-FU Cetuximab+FP (5-FU+CDDP) Cetuximab+RT FP (5-FU+CDDP)+Pembrolizumab Nivolumab (240mg) Nivolumab (480mg) PCE (PTX+CBDCA+Cetuximab) Pembrolizumab (200mg) Pembrolizumab (400mg) Pembrolizumab (MSI-High固形癌) (400mg) PTX+Cetuximab weekly CDDP+RT
